The DOI matches its Crossref record.
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Cytochrome P450 2C is an EDHF synthase in coronary arteries
Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D. R., Fleming, I., & Busse, R. (1999) · Nature · doi:10.1038/46816 · Cited by 911
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
Miners, J. O., & Birkett, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00721.x · Cited by 844
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527
Resistance to clopidogrel: A review of the evidence
Nguyen, T. A., Diodati, J. G., & Pharand, C. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.034 · Cited by 520
Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Hamelin, B. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01147-4 · Cited by 468
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 423
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
Neuvonen, P. J., Kantola, T., & Kivistö, K. T. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90165-5 · Cited by 406
Cytochrome P450 and Vascular Homeostasis
Fleming, I. (2001) · Circulation Research · doi:10.1161/hh2101.099268 · Cited by 383
Fichtenbaum, C. J., Gerber, J. G., Rosenkranz, S. L., Segal, Y., Aberg, J. A., Blaschke, T., Alston, B., Fang, F., Kosel, B., & Aweeka, F. (2002) · AIDS · doi:10.1097/00002030-200203080-00008 · Cited by 338
Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., & Sugiyama, Y. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.461 · Cited by 282
HMG-CoA Reductase Inhibitors and Myotoxicity
Ucar, M., Mjorndal, T., & Dahlqvist, R. (2000) · Drug Safety · doi:10.2165/00002018-200022060-00003 · Cited by 279
(1997) · PubMed · Cited by 271
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
Kajinami, K., Takekoshi, N., & Saito, Y. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00116.x · Cited by 136
Statin myotoxicity: a review of genetic susceptibility factors
Needham, M., & Mastaglia, F. L. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.09.011 · Cited by 108
Choi, H. Y., Bae, K.-S., Cho, S.-H., Ghim, J.-L., Choe, S., Jung, J. A., Jin, S.-J., Kim, H.-S., & Lim, H.-S. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000176 · Cited by 49
Dose Dependency of Fluvastatin Pharmacokinetics in Serum Determined by Reversed Phase HPLC
Siekmeier, R., Lattke, P., Mix, C., Park, J.-W., & Jaross, W. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600205 · Cited by 30
Enajat, M., Teerenstra, S., van Kuilenburg, J. T., van Sorge-Greve, A. H. N., Albers-Akkers, M. T. H., Verheugt, F. W. A., & Pop, G. A. M. (2009) · Drugs & Aging · doi:10.2165/10558450-000000000-00000 · Cited by 13
Metadata
- Authors
- Transon, C., Leemann, T., & Dayer, P.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 1996-05-14
- Volume
- 50
- Issue
- 3
- Pages
- 209-215
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2074022399
- Cited by
- 173
- References
- 0
- FWCI
- 10.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.